Inactive Instrument

Genovis AB Share Price Nasdaq Stockholm

Equities

Medical Equipment, Supplies & Distribution

End-of-day quote Nasdaq Stockholm
- SEK - Intraday chart for Genovis AB
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site

Financials

Sales 2024 * 154M 14.61M 1.15B Sales 2025 * 189M 18.01M 1.42B Capitalization 1.96B 187M 14.73B
Net income 2024 * 40M 3.81M 300M Net income 2025 * 49M 4.66M 368M EV / Sales 2024 * 12.1 x
Net cash position 2024 * 108M 10.3M 812M Net cash position 2025 * 128M 12.17M 959M EV / Sales 2025 * 9.7 x
P/E ratio 2024 *
48.5 x
P/E ratio 2025 *
40.9 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 0%
More Fundamentals * Assessed data
Genovis AB (publ.) Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Carthesian Therapeutics Terminates Genovis AB (Publ.) Licence Agreement CI
Genovis AB (publ.) Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Genovis AB (publ.) Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Genovis to Get $1 Million Milestone Payment for Xork Development MT
Genovis AB (publ.) Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Genovis AB (publ.) Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Genovis Launch Innovative Igm-Specific Protease with Wide-Ranging Applications in Life Science Markets CI
Genovis AB (publ.) Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
ArcticZymes Technologies ASA and Genovis AB Announce Collaboration to Speed Up Penetration and Growth in the Chinese Market CI
Genovis AB (publ.) Reports Earnings Results for the Fourth Quarter Ended December 31, 2022 CI
Genovis AB (publ.) Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Genovis AB (publ.) Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
Genovis AB (publ.) Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 CI
Genovis Signs Supply Agreement With US Biotech Company; Shares Rise 7% MT
More news
Managers TitleAgeSince
Chief Executive Officer 53 31/12/01
Director of Finance/CFO 53 31/12/21
Chief Tech/Sci/R&D Officer 40 31/12/16
Members of the board TitleAgeSince
Chairman 72 04/05/20
Director/Board Member 63 31/12/18
Director/Board Member 75 31/12/13
More insiders
Genovis AB is a Sweden-based company engaged in the research and development, production and marketing of technologies and products for cellular research. The Company offers products within two product portfolios, namely protein portfolio and nano portfolio. The protein portfolio develops products within the areas of cancer, inflammatory and autoimmune diseases. The portfolio comprises FabRICATOR, a genetically modified enzyme the cleaves antibodies in two parts, and IgGZERO, a protein that specifically cleaves the sugar molecules that occur naturally on antibodies. The products within the nano portfolio are primarily directed at the preclinical market. The Company markets and sells its products through dealers and distributors in the European, North American and Asian continents. As of December 31, 2011, it operated a wholly owned subsidiary, Eijdo Research AB.
Calendar
More about the company
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW